 The FDA has approved Provention Bio Incs NASDAQ: PRVB proceeding to populate the popPK model with data collected from patients receiving therapeutic doses of teplizumab PKPD substudy. Related Link: Provention Bios Teplizumab Application Receives CRL For Type-1 Diabetes; Stock Drops 